Document is current
Any future updates will be listed below
-
Authors
Huhn, Gregory D.
Eron, Joseph J.
Girard, Pierre-Marie
Orkin, Chloe
Molina, Jean-Michel
DeJesus, Edwin
Petrovic, Romana
Luo, Donghan
Van Landuyt, Erika
Lathouwers, Erkki
Nettles, Richard E.
Brown, Kimberley
Wong, Eric Y.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02269917 at ClinicalTrials.govDocuments that mention this clinical trial
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
https://doi.org/10.1186/s12981-019-0235-1
Rates of adverse events of antiretroviral therapy in women living with HIV/AIDS: a systematic review and meta-analysis
https://doi.org/10.1136/bmjopen-2023-079292
-
Funding
Funding for this research was provided by:
Janssen Scientific Affairs, LLC
- License Information
-
More Information
Article History
Received: 6 May 2019
Accepted: 8 August 2019
First Online: 29 August 2019
Ethics approval and consent to participate
: The EMERALD protocol was reviewed and approved by institutional review boards or independent ethics committees. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. All patients provided written, informed consent prior to the start of the study.
: Not applicable.
: GDH has received research or grant support from Gilead, ViiV, Janssen, Proteus, and the US National Institutes of Health; he has also served as a consultant to Janssen, Gilead, and ViiV. JJE received research grants from Janssen, Gilead, and ViiV; and has served as a consultant to Bristol-Myers Squibb, Merck, Janssen, Gilead, and ViiV. P-MG has received grant/research support from Merck; served on advisory committees or review panels for Merck, Roche, ViiV, Gilead, and Janssen; and served as a speaker/teacher for Merck and Tibotec. CO has received speaker honoraria or consulting fees for attending speakers bureaus or advisory boards for, and has received research grants from, Janssen, Merck, ViiV, and Gilead. J-MM has received honoraria for participation in advisory boards for Gilead and Merck; and has received a research grant from Merck. EDJ has participated in a speaker bureau for Gilead, and advisory boards for Gilead, Janssen, and Theratechnologies. RP is a former contractor for Janssen. DL, EVL, EL, REN, KB, and EYW are full-time employees of Janssen.
